Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending

Altimmune (ALT) reported a net loss of $31.6 million for the third quarter of 2026, an increase from the $19.0 million loss recorded in the prior-year period. The widened loss was primarily driven by a significant rise in research and development expenses, which reached $27.0 million as the company advances its Phase 3 MASH trial and ongoing Phase 2 ALD trials. Despite the net loss, the company maintains a strong liquidity position with $480 million in cash and investments as of September 30, 2026. Management expects this capital to provide an operating runway through the anticipated 52-week data readout for its PERFORMA MASH trial scheduled for 2029. The company is currently focused on building a liver disease franchise centered around its pemvidutide program.

5 articles from 3 sources · updated

Coverage